Galapagos has found a buyer for its once-promising JAK inhibitor Jyseleca (filgotinib), signing a letter of intent to transfer the drug and related operations to Alfasigma of Italy.Under the deal, Galapagos will transfer its Jyseleca marketing authorizations in Europe and the U.K. along with roughly 400 employees who are involved in the development, marketing and […]